Harrow (Harrow) Float Percentage Of Total Shares Outstanding : 70.52% (As of May. 23, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Harrow Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Harrow's float shares is 24.95 Mil. Harrow's total shares outstanding is 35.38 Mil. Harrow's float percentage of total shares outstanding is 70.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Harrow's Insider Ownership is 18.84%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Harrow's Institutional Ownership is 25.07%.

Harrow Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Harrow's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	24.95	/	35.38
	=	70.52%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harrow (Harrow) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205

Website

https://www.harrow.com

Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.

Executives

Mark L Baum	director, 10 percent owner, officer: Chief Executive Officer	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence	director	354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll	officer: VP, Accounting and Reporting	437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg	director	102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks	director	40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer	director, 10 percent owner, officer: Chairman of the Board	1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc	other: Institutional Investor	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	other: Managing Mbr of Longboard Cap.	1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards	officer: Chief Operating Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi	director	2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni	10 percent owner	1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek	officer: Chief Commercial Officer	12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130